PI
HRTX icon

PFS Investments’s Heron Therapeutics HRTX Stock Holding History

PFS Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$18K Buy
15,231
+1,154
+8% +$2.06K ﹤0.01% 512
2023
Q1 		$32K Buy
+14,077
New +$35.3K ﹤0.01% 501

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

PFS Investments's HRTX Position: Q2 2023 in Review

PFS Investments increased its Heron Therapeutics (HRTX) stake by 8.2% in Q2 2023, buying an estimated $2.06K and bringing the position to 15,231 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #512.

PFS Investments first reported a position in HRTX in Q1 2023 and has held it in 2 quarters since. The position peaked at $32K in Q1 2023. 148 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • PFS Investments held 15,231 shares of Heron Therapeutics worth $18K as of Q2 2023.
  • PFS Investments bought 1,154 Heron Therapeutics shares in Q2 2023, an estimated $2.06K.
  • Heron Therapeutics made up ﹤0.01% of PFS Investments's portfolio in Q2 2023, its #512 holding.
  • PFS Investments first reported a position in Heron Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • PFS Investments's Heron Therapeutics position peaked at $32K in Q1 2023.
  • 148 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.